CidaraLogo (1).jpg
Cidara Therapeutics to Present at the 18th Annual Needham Healthcare Conference
April 03, 2019 16:04 ET | Cidara Therapeutics, Inc.
SAN DIEGO, April 03, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that...
CidaraLogo (1).jpg
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results
February 28, 2019 16:24 ET | Cidara Therapeutics, Inc.
SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
novan logo.jpg
Novan Phase 2 Molluscum Contagiosum Trial Achieves Statistical Significance in Preliminary Top Line Results
November 14, 2018 06:30 ET | Novan, Inc.
Higher rates of complete clearance of all molluscum lesions at Week 12 for the two highest doses, SB206 8% and 12% twice-daily, more than double the rate observed in the vehicle groupClear treatment...
novan logo.jpg
Novan Publication Supports Women’s Health Business Unit Initiative and Nitric Oxide’s Potential Against HPV-Associated Diseases
November 01, 2018 08:05 ET | Novan, Inc.
Data from SB206 Phase 2 clinical trial in external genital warts have been published in the Journal of Drugs in DermatologySB206 was efficacious and well tolerated in the trialAdvancement of the late...
novan logo.jpg
Novan Creates Dedicated Women’s Health Business Unit
October 25, 2018 07:05 ET | Novan, Inc.
Business unit will focus on Novan’s proprietary nitric oxide technology and its application to target high-risk human papillomavirus (HPV) and associated cancers affecting women such as cervical...
novan logo.jpg
Novan Expands Nitric Oxide Dermatology Business Partnership with Sato in Japan
October 08, 2018 08:00 ET | Novan, Inc.
Expanded license agreement adds SB206 for the treatment of viral skin infections Novan to receive upfront cash consideration of approximately 1.25 billion JPY (~$11.0 million), payable over the next...
novan logo.jpg
Novan’s Phase 2 Molluscum Contagiosum Trial Fully Enrolled: Top Line Results Targeted in November
October 01, 2018 08:05 ET | Novan, Inc.
Trial enrollment completed meaningfully ahead of scheduleTop line results targeted to be communicated no later than mid-NovemberFavorable and consistent safety profile of SB206 enabled escalation to...
CidaraLogo (1).jpg
Cidara Provides Corporate Update and Reports Second Quarter 2018 Financial Results
August 08, 2018 16:30 ET | Cidara Therapeutics, Inc.
SAN DIEGO, Aug. 08, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
CidaraLogo (1).jpg
Cidara Provides Corporate Update and Reports First Quarter 2018 Financial Results
May 10, 2018 16:05 ET | Cidara Therapeutics, Inc.
SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial...
2019 logo_150x35_jpg.jpg
Novan Announces First Patient Dosed in Phase 2 Molluscum Contagiosum Trial with SB206
January 25, 2018 09:00 ET | Novan, Inc.
MORRISVILLE, N.C., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the first patient has been dosed in the Company's Phase 2 clinical...